Source: LEO Pharma has entered a strategic partnership with AstraZeneca for new medicines for atopic dermatitis and psoriasis, major skin diseases with a significant unmet medical need. Under the move, LEO gains a the global licence to AZ' tralokinumab in skin diseases and an exclusive licence to brodalumab in Europe.…...